IRadimed Stock Forecast, Price & News

IRadimed (NASDAQ:IRMD) Frequently Asked Questions

Is IRadimed a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IRadimed in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRadimed stock.
View analyst ratings for IRadimed or view top-rated stocks.

How has IRadimed's stock price been impacted by COVID-19?

IRadimed's stock was trading at $22.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IRMD shares have increased by 99.9% and is now trading at $45.00.
View which stocks have been most impacted by COVID-19.

Are investors shorting IRadimed?

IRadimed saw a decrease in short interest in November. As of November 15th, there was short interest totaling 66,000 shares, a decrease of 33.7% from the October 31st total of 99,500 shares. Based on an average daily trading volume, of 35,000 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.0% of the shares of the company are short sold.
View IRadimed's Short Interest.

When is IRadimed's next earnings date?

IRadimed is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for IRadimed.

How were IRadimed's earnings last quarter?

IRadimed Co. (NASDAQ:IRMD) posted its earnings results on Thursday, October, 28th. The medical equipment provider reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. IRadimed had a trailing twelve-month return on equity of 9.44% and a net margin of 15.77%. During the same period last year, the firm posted $0.09 EPS.
View IRadimed's earnings history.

What guidance has IRadimed issued on next quarter's earnings?

IRadimed updated its FY 2021 earnings guidance on Friday, November, 5th. The company provided earnings per share (EPS) guidance of $0.700-$0.710 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.620. The company issued revenue guidance of $41.40 million-$41.60 million, compared to the consensus revenue estimate of $40.16 million.

What price target have analysts set for IRMD?

1 Wall Street analysts have issued 1-year target prices for IRadimed's shares. Their forecasts range from $42.00 to $42.00. On average, they expect IRadimed's share price to reach $42.00 in the next year. This suggests that the stock has a possible downside of 6.7%.
View analysts' price targets for IRadimed or view top-rated stocks among Wall Street analysts.

Who are IRadimed's key executives?

IRadimed's management team includes the following people:

• Roger Susi, Chairman, President & Chief Executive Officer
• Christopher K. Scott, Secretary, Chief Operating & Financial Officer
• Chris Williamson, Vice President-Information Technology
• Lynn Neuhardt, Vice President-Research & Development
• MaryBeth Smith, Vice President-Worldwide Sales

Who are some of IRadimed's key competitors?

Some companies that are related to IRadimed include Glaukos (GKOS), Inovio Pharmaceuticals (INO), Paragon 28 (FNA), Procept BioRobotics (PRCT), Silk Road Medical (SILK), Atrion (ATRI), Pulmonx (LUNG), Cerus (CERS), Alphatec (ATEC), OrthoPediatrics (KIDS), LeMaitre Vascular (LMAT), AngioDynamics (ANGO), Sight Sciences (SGHT), Bioventus (BVS) and Treace Medical Concepts (TMCI).
View all of IRMD's competitors.

What other stocks do shareholders of IRadimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRadimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR).

What is IRadimed's stock symbol?

IRadimed trades on the NASDAQ under the ticker symbol "IRMD."

Who are IRadimed's major shareholders?

IRadimed's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.69%), BlackRock Inc. (3.38%), Russell Investments Group Ltd. (1.51%), Mondrian Investment Partners LTD (1.11%), Rice Hall James & Associates LLC (0.98%) and Geode Capital Management LLC (0.82%). Company insiders that own IRadimed stock include Anthony Vuoto, Brent Johnson, Christopher K Scott, James B Hawkins, Louis S Waldman, Monty K Allen, Monty K Allen and Roger E Susi.
View institutional ownership trends for IRadimed.

Which major investors are selling IRadimed stock?

IRMD stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Mondrian Investment Partners LTD, Russell Investments Group Ltd., Foundry Partners LLC, California State Teachers Retirement System, Nisa Investment Advisors LLC, Los Angeles Capital Management LLC, and LPL Financial LLC. Company insiders that have sold IRadimed company stock in the last year include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, and Roger E Susi.
View insider buying and selling activity for IRadimed or view top insider-selling stocks.

Which major investors are buying IRadimed stock?

IRMD stock was acquired by a variety of institutional investors in the last quarter, including Hillsdale Investment Management Inc., Bares Capital Management Inc., EAM Investors LLC, Dimensional Fund Advisors LP, Two Sigma Advisers LP, Two Sigma Investments LP, BlackRock Inc., and Millennium Management LLC.
View insider buying and selling activity for IRadimed or or view top insider-buying stocks.

How do I buy shares of IRadimed?

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IRadimed's stock price today?

One share of IRMD stock can currently be purchased for approximately $45.00.

How much money does IRadimed make?

IRadimed has a market capitalization of $555.39 million and generates $31.72 million in revenue each year. The medical equipment provider earns $1.37 million in net income (profit) each year or $0.48 on an earnings per share basis.

How many employees does IRadimed have?

IRadimed employs 110 workers across the globe.

What is IRadimed's official website?

The official website for IRadimed is www.iradimed.com.

Where are IRadimed's headquarters?

IRadimed is headquartered at 1025 Willa Springs Dr., Winter Springs FL, 32708.

How can I contact IRadimed?

IRadimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at (407) 677-8022, via email at [email protected], or via fax at 407-677-5037.